Cogent Biosciences, Inc. APIC, Share-based Payment Arrangement, Increase for Cost Recognition
Cogent Biosciences, Inc. (COGT) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $17.11 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2026-08-10
- Cogent Biosciences, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-06-30 was $17.11M, a 76.07% increase year-over-year.
- Cogent Biosciences, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-03-31 was $16.91M, a 68.94% increase year-over-year.
- Cogent Biosciences, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-09-30 was $10.60M, a 2.37% increase year-over-year.
- Cogent Biosciences, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-06-30 was $9.72M, a 2.96% decline year-over-year.
- Cogent Biosciences, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2025 was $46.08M, a 15.95% increase from fiscal 2024.
- Cogent Biosciences, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2024 was $39.74M, a 29.78% increase from fiscal 2023.
- Cogent Biosciences, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2023 was $30.62M, a 66.71% increase from fiscal 2022.
- Cogent Biosciences, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2022 was $18.37M, a 60.76% increase from fiscal 2021.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month |
|---|---|---|---|---|
| 2026-06-30 | $17.11M 10-Q · filed 2026-08-10 | $34.02M derived: sum of 2 quarters · filed 2026-08-10 | ||
| 2026-03-31 | $16.91M 10-Q · filed 2026-08-10 | |||
| 2025-12-31 | $46.08M 10-K · filed 2026-02-17 | |||
| 2025-09-30 | $10.60M 10-Q · filed 2025-11-07 | $20.32M derived: sum of 2 quarters · filed 2026-08-10 | $30.33M derived: sum of 3 quarters · filed 2026-08-10 | |
| 2025-06-30 | $9.72M 10-Q · filed 2026-08-10 | $19.72M derived: sum of 2 quarters · filed 2026-08-10 | ||
| 2025-03-31 | $10.01M 10-Q · filed 2026-08-10 | |||
| 2024-12-31 | $39.74M 10-K · filed 2026-02-17 | |||
| 2024-09-30 | $10.36M 10-Q · filed 2025-11-07 | $20.37M derived: sum of 2 quarters · filed 2025-11-07 | $29.76M derived: sum of 3 quarters · filed 2025-11-07 | |
| 2024-06-30 | $10.01M 10-Q · filed 2025-11-07 | $19.41M derived: sum of 2 quarters · filed 2025-11-07 | ||
| 2024-03-31 | $9.39M 10-Q · filed 2025-11-07 | |||
| 2023-12-31 | $30.62M 10-K · filed 2026-02-17 | |||
| 2023-09-30 | $8.76M 10-Q · filed 2024-11-12 | $15.92M derived: sum of 2 quarters · filed 2024-11-12 | $21.77M derived: sum of 3 quarters · filed 2024-11-12 | |
| 2023-06-30 | $7.16M 10-Q · filed 2024-11-12 | $13.01M derived: sum of 2 quarters · filed 2024-11-12 | ||
| 2023-03-31 | $5.85M 10-Q · filed 2024-11-12 | |||
| 2022-12-31 | $18.37M 10-K · filed 2025-02-25 | |||
| 2022-09-30 | $4.62M 10-Q · filed 2023-11-07 | $9.16M derived: sum of 2 quarters · filed 2023-11-07 | $13.33M derived: sum of 3 quarters · filed 2023-11-07 | |
| 2022-06-30 | $4.53M 10-Q · filed 2023-11-07 | $8.71M derived: sum of 2 quarters · filed 2023-11-07 | ||
| 2022-03-31 | $4.17M 10-Q · filed 2023-11-07 | |||
| 2021-12-31 | $11.43M 10-K · filed 2024-02-26 | |||
| 2021-09-30 | $3.46M 10-Q · filed 2022-11-14 | $6.05M derived: sum of 2 quarters · filed 2022-11-14 | $7.57M derived: sum of 3 quarters · filed 2022-11-14 | |
| 2021-06-30 | $2.59M 10-Q · filed 2022-11-14 | $4.11M derived: sum of 2 quarters · filed 2022-11-14 | ||
| 2021-03-31 | $1.52M 10-Q · filed 2022-11-14 | |||
| 2020-12-31 | $5.75M 10-K · filed 2022-03-15 | |||
| 2020-09-30 | $3.51M 10-Q · filed 2021-11-10 | $4.38M derived: sum of 2 quarters · filed 2021-11-10 | $4.89M derived: sum of 3 quarters · filed 2021-11-10 | |
| 2020-06-30 | $870.00K 10-Q · filed 2021-11-10 | $1.38M derived: sum of 2 quarters · filed 2021-11-10 | ||
| 2020-03-31 | $507.00K 10-Q · filed 2021-11-10 | |||
| 2019-12-31 | $3.24M 10-K · filed 2021-03-16 | |||
| 2019-09-30 | $788.00K 10-Q · filed 2020-11-09 | $1.67M derived: sum of 2 quarters · filed 2020-11-09 | $2.40M derived: sum of 3 quarters · filed 2020-11-09 | |
| 2019-06-30 | $885.00K 10-Q · filed 2020-11-09 | $1.61M derived: sum of 2 quarters · filed 2020-11-09 | ||
| 2019-03-31 | $726.00K 10-Q · filed 2020-11-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |